Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Rosiglitazone and cardiotoxicity--weighing the evidence.

Nathan DM.

N Engl J Med. 2007 Jul 5;357(1):64-6. Epub 2007 Jun 5. No abstract available.

2.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group.

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

3.

Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.

Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E.

Diabetes Care. 2002 Jul;25(7):1251-2. No abstract available.

PMID:
12087036
4.
5.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
6.

A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.

Chang Y, Choi NK, Hahn S, Park BJ.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1072-3; author reply 1073-4. No abstract available.

PMID:
17907252
7.

Rosiglitazone + glimepiride: new drug. Another combination product to avoid.

[No authors listed]

Prescrire Int. 2007 Aug;16(90):144. No abstract available.

PMID:
17726795
8.

Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?

Standl E, Schnell O.

Diabetes Care. 2008 Feb;31 Suppl 2:S136-9. doi: 10.2337/dc08-s234. No abstract available.

PMID:
18227474
9.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
10.

Rosiglitazone/glimepiride (Avandaryl) for diabetes.

[No authors listed]

Med Lett Drugs Ther. 2006 Mar 13;48(1230):22-4. No abstract available.

PMID:
16538189
11.

Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.

Orbay E, Sargin M, Sargin H, Gözü H, Bayramiçli OU, Yayla A.

Endocr J. 2004 Dec;51(6):521-7.

12.

Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.

Garber AJ.

Diabetes Obes Metab. 2000 Jun;2(3):139-47. Review. No abstract available.

PMID:
11220549
13.

Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

[No authors listed]

Harv Heart Lett. 2007 Aug;17(12):1-2. No abstract available.

PMID:
17717888
14.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association.

Circulation. 2003 Dec 9;108(23):2941-8. Review. No abstract available.

15.

Rosiglitazone and cardiovascular risk: weighing recent evidence.

Stafylas PC, Sarafidis PA, Lasaridis AN.

J Cardiometab Syndr. 2007 Fall;2(4):295-6. Review. No abstract available.

16.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724
17.

Thiazolidinedione derivatives in type 2 diabetes mellitus.

Tack CJ, Smits P.

Neth J Med. 2006 Jun;64(6):166-74. Review.

18.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
19.

[Rosiglitazone: no increase in cardiovascular mortality].

Jazet IM, Meinders AE.

Ned Tijdschr Geneeskd. 2009;153:A942. Dutch.

PMID:
19930745
20.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014

Supplemental Content

Support Center